Richard D Carvajal1, Michael K Wong2, John A Thompson3, Michael S Gordon4, Karl D Lewis5, Anna C Pavlick6, Jedd D Wolchok7, Patrick B Rojas8, Jonathan D Schwartz8, Agop Y Bedikian9. 1. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address: carvajar@mskcc.org. 2. USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA. 3. Seattle Cancer Care Alliance, Seattle, WA, USA. 4. Pinnacle Oncology Hematology, Scottsdale, AZ, USA. 5. University of Colorado Denver, Aurora, CO, USA. 6. New York University, New York, NY, USA. 7. Memorial Sloan-Kettering Cancer Center, New York, NY, USA. 8. ImClone Systems LLC, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA. 9. MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: To evaluate the efficacy and safety of ramucirumab (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with dacarbazine in chemotherapy-naïve patients with metastatic melanoma (MM). METHODS: Eligible patients received ramucirumab (10mg/kg) + dacarbazine (1000 mg/m(2)) (Arm A) or ramucirumab only (10mg/kg) (Arm B) every 3 weeks. The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. FINDINGS: Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. INTERPRETATION:Ramucirumab alone or in combination with dacarbazine was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.
RCT Entities:
BACKGROUND: To evaluate the efficacy and safety of ramucirumab (IMC-1121B; LY3009806), a fully human monoclonal antibody targeting the vascular endothelial growth factor receptor-2, alone and in combination with dacarbazine in chemotherapy-naïve patients with metastatic melanoma (MM). METHODS: Eligible patients received ramucirumab (10mg/kg) + dacarbazine (1000 mg/m(2)) (Arm A) or ramucirumab only (10mg/kg) (Arm B) every 3 weeks. The primary end-point was progression-free survival (PFS); secondary end-points included overall survival (OS), overall response and safety. FINDINGS: Of 106 randomised patients, 102 received study treatment (Arm A, N=52; Arm B, N=50). Baseline characteristics were similar in both arms. Median PFS was 2.6 months (Arm A) and 1.7 months (Arm B); median 6-month PFS rates were 30.7% and 17.9% and 12-month PFS rates were 23.7% and 15.6%, respectively. In Arm A, 9 (17.3%) patients had partial response (PR) and 19 (36.5%), stable disease (SD); PR and SD in Arm B were 2 (4.0%) and 21 (42.0%), respectively. Median OS was 8.7 months in Arm A and 11.1 months in Arm B. Patients in both arms tolerated the treatment with limited Grade 3/4 toxicities. INTERPRETATION:Ramucirumab alone or in combination with dacarbazine was associated with an acceptable safety profile in patients with MM. Although the study was not powered for comparison between treatment arms, PFS appeared greater with combination therapy. Sustained disease control was observed on both study arm.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: M Prewett; J Huber; Y Li; A Santiago; W O'Connor; K King; J Overholser; A Hooper; B Pytowski; L Witte; P Bohlen; D J Hicklin Journal: Cancer Res Date: 1999-10-15 Impact factor: 12.701
Authors: Paolo Antonio Ascierto; Enrico Leonardi; Alessandro Ottaiano; Maria Napolitano; Stefania Scala; Giuseppe Castello Journal: Anticancer Res Date: 2004 Nov-Dec Impact factor: 2.480
Authors: Dina Chelouche Lev; Amir Onn; Vladislava O Melinkova; Claudia Miller; Valerie Stone; Maribelis Ruiz; Eric C McGary; Honnavara N Ananthaswamy; Janet E Price; Menashe Bar-Eli Journal: J Clin Oncol Date: 2004-05-03 Impact factor: 44.544
Authors: M F Avril; S Aamdal; J J Grob; A Hauschild; P Mohr; J J Bonerandi; M Weichenthal; K Neuber; T Bieber; K Gilde; V Guillem Porta; J Fra; J Bonneterre; P Saïag; D Kamanabrou; H Pehamberger; J Sufliarsky; J L Gonzalez Larriba; A Scherrer; Y Menu Journal: J Clin Oncol Date: 2004-03-15 Impact factor: 44.544
Authors: Marie Viala; Marie Vinches; Marie Alexandre; Caroline Mollevi; Anna Durigova; Nadia Hayaoui; Krisztian Homicsko; Alice Cuenant; Céline Gongora; Luca Gianni; Diego Tosi Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640